These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 27076760)
1. Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer. Li W; Ji YH; Li CX; Liu ZY; Li N; Fang L; Chang J; Tan J World J Gastroenterol; 2016 Apr; 22(14):3758-68. PubMed ID: 27076760 [TBL] [Abstract][Full Text] [Related]
2. Antitumor Effect of Nanoparticle Ming H; Fang L; Gao J; Li C; Ji Y; Shen Y; Hu Y; Li N; Chang J; Li W; Tan J AJR Am J Roentgenol; 2017 May; 208(5):1116-1126. PubMed ID: 28301223 [TBL] [Abstract][Full Text] [Related]
3. Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression. Li W; Liu Z; Li C; Li N; Fang L; Chang J; Tan J J Cancer Res Clin Oncol; 2016 Mar; 142(3):619-32. PubMed ID: 26573511 [TBL] [Abstract][Full Text] [Related]
4. Radioiodine-labeled anti-epidermal growth factor receptor binding bovine serum albumin-polycaprolactone for targeting imaging of glioblastoma. Li C; Tan J; Chang J; Li W; Liu Z; Li N; Ji Y Oncol Rep; 2017 Nov; 38(5):2919-2926. PubMed ID: 28901480 [TBL] [Abstract][Full Text] [Related]
6. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052 [TBL] [Abstract][Full Text] [Related]
7. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2. van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932 [TBL] [Abstract][Full Text] [Related]
8. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666 [TBL] [Abstract][Full Text] [Related]
9. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070 [TBL] [Abstract][Full Text] [Related]
10. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064 [TBL] [Abstract][Full Text] [Related]
11. 131I-recombinant human EGF has antitumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR. Li YC; Xu WY; Tan TZ; He S Nucl Med Biol; 2004 May; 31(4):435-40. PubMed ID: 15093813 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047 [TBL] [Abstract][Full Text] [Related]
14. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Chen P; Cameron R; Wang J; Vallis KA; Reilly RM J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194 [TBL] [Abstract][Full Text] [Related]
15. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts. Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration. Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787 [TBL] [Abstract][Full Text] [Related]
17. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929 [TBL] [Abstract][Full Text] [Related]
18. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy. Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909 [TBL] [Abstract][Full Text] [Related]
19. Combinational treatment with microRNA‑133b and cetuximab has increased inhibitory effects on the growth and invasion of colorectal cancer cells by regulating EGFR. Zhou J; Lv L; Lin C; Hu G; Guo Y; Wu M; Tian B; Li X Mol Med Rep; 2015 Oct; 12(4):5407-14. PubMed ID: 26151111 [TBL] [Abstract][Full Text] [Related]
20. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]